search
Back to results

Investigating My Active and Healthy Aging (my-AHA)

Primary Purpose

Frail Elderly Syndrome, Cognitive Impairment, Physical Dependence

Status
Unknown status
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
My-AHA platform
Sponsored by
University of Turin, Italy
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Frail Elderly Syndrome focused on measuring Frailty, Physical impairment, Cognitive decline, ICT

Eligibility Criteria

60 Years - 85 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

INCLUSION CRITERIA for pre-screening

  1. Age: over 60 yrs
  2. Able to stand and walk unassisted
  3. Free of significant cognitive impairment (age-corrected Mini Mental State Examination Test ≥ 24)
  4. Free of clinically significant mood disturbance (HADS-Anxiety <15; HADS-depression < 15)
  5. Free of any acute or unstable medical conditions
  6. Able to understand directions and participate in the protocol
  7. Able to sign informed consent

Subjects will be enrolled in the study if they meet one or two of the Fried et al. (2001) criteria for Frailty (Pre-Frailty status).

1. Shrinking, evidenced by weight loss (unintentional) ≥ 4.5 kg unintentional in prior 12 months; or at follow-up assessment ≥ 5% of body weight in prior 12 months.

2, Weakness. Grip strength in lowest 20% at baseline adjusted for gender and BMI.

3. Poor endurance and energy. Self-report of exhaustion as indicated by responses to 2 questions on Center for Epidemiologic Studies Depression (CES-D) scale.

4. Slowness .Time to walk 15ft (4.57m) ≤ slowest 20% adjusted for gender and standing height.

5. Low physical activity level. Lowest quintile (25%) by gender for weighted kcal expenditure per week at baseline.

EXCLUSION CRITERIA

Participant excluded if meets 1 or more of below:

Mobility problems

  1. cannot stand and ambulate unassisted
  2. painful arthritis, spinal stenosis, amputation, or painful foot lesions that limits balance and mobility,

Concurrent chronic disease independently contributing to frailty

  1. suffers from a significant neurodegenerative disorder, e.g.

    1. Alzheimer's disease
    2. Lewy body dementia
    3. Frontotemporal Lobar Degeneration, Fronto-Temporal Dementia
    4. Parkinson's disease
    5. multiple sclerosis
    6. progressive supranuclear palsy
    7. amyotrophic lateral sclerosis
    8. hydrocephalus
    9. Huntington's disease
    10. prion diseases
  2. affected by severe peripheral nervous system and/or neuromuscular disorders, e.g.

    1. chronic inflammatory demyelinating polyneuropathy
    2. myasthenia gravis
    3. multiple sclerosis
    4. polymyositis

Concomitant injury or disease known

  1. clinical evidence or history of stroke (within 2 yrs) to impact independently cognitive,
  2. clinical evidence or history of transient ischemic attack (within 6 months) psychological or physical function
  3. significant head injury with associated loss of consciousness, skull fracture or persisting cognitive impairment (2 years)
  4. epilepsy (a single prior seizure is considered acceptable)
  5. if meet Diagnostic and Statistical Manual 5 (DSM-5) criteria for:

    1. major depressive disorder (current)
    2. schizophrenia or other psychotic disorders (lifetime)
    3. bipolar disorder (within the past 5 years
    4. substance (including alcohol) related disorders (within the past 2 years)

Presence of cognitive, sensory or

  1. have language deficits that impair testing perceptual deficits that interfere with assessment tasks
  2. have significant visual impairment
  3. have a significant hearing loss

Presence of other conditions or diseases that will compromise ability to undertake interventions (especially physical)

  1. have clinically significant cardiovascular disease, i.e:

    1. hospitalization for acute coronary syndrome (acute myocardial infarction or unstable, angina)
    2. symptoms consistent with angina pectoris, within the 12 months
    3. signs or symptoms of clinical heart failure within the 12 months
    4. evidence of uncontrolled atrial fibrillation
    5. a cardiac pacemaker
  2. preexisting or current signs or symptoms of respiratory failure, e.g.

    1. chronic obstructive pulmonary disease
    2. bronchial asthma
    3. lung fibrosis
    4. other respiratory disease
  3. untreated hypertension
  4. metastatic cancer or immunosuppressive therapy
  5. concurrent acute or chronic clinically significant immunologic, hepatic (such as presence of encephalopathy or ascites), or endocrine disease (not adequately treated).

Unacceptable Test/Laboratory Values

1. Postural hypotension (fall in systolic blood pressure of greater than 30 mmHg or fall in diastolic blood pressure of greater than 20 mmHg on standing compared to sitting) at the time of screening. Subjects who present at the time of screening with postural hypotension yet have no known history of postural hypotension, nor underlying medical condition related to hypotension, may be rescreened

Sites / Locations

  • Aging Brain and Memory Clinic, Department of Neuroscience, University of TorinoRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Cases

Controls

Arm Description

Pre-frail subjects will use an ICT platform (my-AHA platform) embedded in a mobile phone and a fit-band that will continuously monitor physical and cognitive activities. Interventions regarding physical, cognitive, psychological and social domains will be prescribed and monitored through the my-AHA platform. In addition, sleep and dietary habits will be investigated and tailored interventions will be suggested.

Pre-frail subjects will be followed according to "best standard of care" protocols. Interventions regarding physical, cognitive, psychological and social domains will be prescribed. In addition, sleep and dietary habits will be investigated and tailored interventions will be suggested.

Outcomes

Primary Outcome Measures

Conversion rate from a pre-frail status to a frail status (Fried criteria)
Comparison of conversion rate in cases and controls between pre-frail status fo frail status

Secondary Outcome Measures

Full Information

First Posted
October 22, 2017
Last Updated
May 9, 2018
Sponsor
University of Turin, Italy
search

1. Study Identification

Unique Protocol Identification Number
NCT03342976
Brief Title
Investigating My Active and Healthy Aging
Acronym
my-AHA
Official Title
Evaluation of an ICT-based Platform for Early Detection and Intervention to Prevent Frailty in Older Adults
Study Type
Interventional

2. Study Status

Record Verification Date
May 2018
Overall Recruitment Status
Unknown status
Study Start Date
May 3, 2018 (Actual)
Primary Completion Date
September 30, 2019 (Anticipated)
Study Completion Date
December 31, 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Turin, Italy

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a multicenter, multicultural, randomized control trial. Participants will be recruited from 10 centers located in Italy, Germany, Austria, Spain, United Kingdom, Belgium, Sweden, Japan, South Korea and Australia. The main objective of the study is to examine the efficacy of a sensor-based platform (my-AHA platform) to assess frailty risks and to deliver tailored interventions in order to prevent in elderly subjects conversion from a pre-frail status to a frailty status.
Detailed Description
In the past decade, frailty has attracted great attention of the scientific community and public health organizations as precursor and contributor of age-related diseases. Frailty is a common clinical syndrome in older adults, affecting 7-12% of the older population, and the occurrence of frailty increases with age and may exceed 45% after age 85 years. Frailty develops when age-associated degenerative processes overwhelm reserve capacity and reparative processes that maintain function of the nervous system as well as other physiologic systems. Overall, frailty consists in the vulnerability of aged population to adverse events as the result of the subtle and progressive metabolic and physical changes. Frailty confers a significantly increased risk for poor health outcomes, incident disability, hospitalization, and mortality. In recent years there has been an emergence of information and communication technology (ICT) -based solutions to support active ageing and tackle frailty, cognitive decline and social isolation of older adults. While these ICT-based solutions are of a certain value regarding diminishing single risks (e.g. fall risk, etc.), there is still a need for a more holistic approach which aims to address all of the individual risk factors together. Also it is necessary to provide tailored interventions based on the outcomes of the risk analysis. This assessment of risk for frailty and provision of individual tailored interventions is the main objective of My-AHA project. My-AHA solution supports active and healthy ageing by enabling early detection and minimization of risks associated with ageing. In these terms the early risk detection considers three fundamental aspects of the life of older adults: physical activity (by considering vital signs data, gait, quality of sleep and in general, physical activity, and fall risk); cognitive activity (by monitor the cognitive level, e.ge.g. in cognitive games); and, psychosocial activities (e.g. by analyzing the emotions and the quality of speech of the users). On the other hand, My-AHA will develop and implement more efficient and effective ICT-based interventions tailored to the early identified risks. The suggested social activities, as well as cognitive and physical trainings and the diet proposed to the older adults via the new platform will help the users in changing their behaviour and in reacting to the consequences of ageing.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Frail Elderly Syndrome, Cognitive Impairment, Physical Dependence
Keywords
Frailty, Physical impairment, Cognitive decline, ICT

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Care Provider
Allocation
Randomized
Enrollment
600 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cases
Arm Type
Active Comparator
Arm Description
Pre-frail subjects will use an ICT platform (my-AHA platform) embedded in a mobile phone and a fit-band that will continuously monitor physical and cognitive activities. Interventions regarding physical, cognitive, psychological and social domains will be prescribed and monitored through the my-AHA platform. In addition, sleep and dietary habits will be investigated and tailored interventions will be suggested.
Arm Title
Controls
Arm Type
Placebo Comparator
Arm Description
Pre-frail subjects will be followed according to "best standard of care" protocols. Interventions regarding physical, cognitive, psychological and social domains will be prescribed. In addition, sleep and dietary habits will be investigated and tailored interventions will be suggested.
Intervention Type
Other
Intervention Name(s)
My-AHA platform
Intervention Description
ICT strategy for early detection of frailties
Primary Outcome Measure Information:
Title
Conversion rate from a pre-frail status to a frail status (Fried criteria)
Description
Comparison of conversion rate in cases and controls between pre-frail status fo frail status
Time Frame
18 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
INCLUSION CRITERIA for pre-screening Age: over 60 yrs Able to stand and walk unassisted Free of significant cognitive impairment (age-corrected Mini Mental State Examination Test ≥ 24) Free of clinically significant mood disturbance (HADS-Anxiety <15; HADS-depression < 15) Free of any acute or unstable medical conditions Able to understand directions and participate in the protocol Able to sign informed consent Subjects will be enrolled in the study if they meet one or two of the Fried et al. (2001) criteria for Frailty (Pre-Frailty status). 1. Shrinking, evidenced by weight loss (unintentional) ≥ 4.5 kg unintentional in prior 12 months; or at follow-up assessment ≥ 5% of body weight in prior 12 months. 2, Weakness. Grip strength in lowest 20% at baseline adjusted for gender and BMI. 3. Poor endurance and energy. Self-report of exhaustion as indicated by responses to 2 questions on Center for Epidemiologic Studies Depression (CES-D) scale. 4. Slowness .Time to walk 15ft (4.57m) ≤ slowest 20% adjusted for gender and standing height. 5. Low physical activity level. Lowest quintile (25%) by gender for weighted kcal expenditure per week at baseline. EXCLUSION CRITERIA Participant excluded if meets 1 or more of below: Mobility problems cannot stand and ambulate unassisted painful arthritis, spinal stenosis, amputation, or painful foot lesions that limits balance and mobility, Concurrent chronic disease independently contributing to frailty suffers from a significant neurodegenerative disorder, e.g. Alzheimer's disease Lewy body dementia Frontotemporal Lobar Degeneration, Fronto-Temporal Dementia Parkinson's disease multiple sclerosis progressive supranuclear palsy amyotrophic lateral sclerosis hydrocephalus Huntington's disease prion diseases affected by severe peripheral nervous system and/or neuromuscular disorders, e.g. chronic inflammatory demyelinating polyneuropathy myasthenia gravis multiple sclerosis polymyositis Concomitant injury or disease known clinical evidence or history of stroke (within 2 yrs) to impact independently cognitive, clinical evidence or history of transient ischemic attack (within 6 months) psychological or physical function significant head injury with associated loss of consciousness, skull fracture or persisting cognitive impairment (2 years) epilepsy (a single prior seizure is considered acceptable) if meet Diagnostic and Statistical Manual 5 (DSM-5) criteria for: major depressive disorder (current) schizophrenia or other psychotic disorders (lifetime) bipolar disorder (within the past 5 years substance (including alcohol) related disorders (within the past 2 years) Presence of cognitive, sensory or have language deficits that impair testing perceptual deficits that interfere with assessment tasks have significant visual impairment have a significant hearing loss Presence of other conditions or diseases that will compromise ability to undertake interventions (especially physical) have clinically significant cardiovascular disease, i.e: hospitalization for acute coronary syndrome (acute myocardial infarction or unstable, angina) symptoms consistent with angina pectoris, within the 12 months signs or symptoms of clinical heart failure within the 12 months evidence of uncontrolled atrial fibrillation a cardiac pacemaker preexisting or current signs or symptoms of respiratory failure, e.g. chronic obstructive pulmonary disease bronchial asthma lung fibrosis other respiratory disease untreated hypertension metastatic cancer or immunosuppressive therapy concurrent acute or chronic clinically significant immunologic, hepatic (such as presence of encephalopathy or ascites), or endocrine disease (not adequately treated). Unacceptable Test/Laboratory Values 1. Postural hypotension (fall in systolic blood pressure of greater than 30 mmHg or fall in diastolic blood pressure of greater than 20 mmHg on standing compared to sitting) at the time of screening. Subjects who present at the time of screening with postural hypotension yet have no known history of postural hypotension, nor underlying medical condition related to hypotension, may be rescreened
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Innocenzo Rainero, MD, PhD
Phone
+39-011-091
Ext
974
Email
innocenzo.rainero@unito.it
First Name & Middle Initial & Last Name or Official Title & Degree
Marcella Caglio, PhD
Phone
+39-011-633
Ext
4763
Email
marcella.caglio@unito.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Georg Aumayr, PhD
Organizational Affiliation
Johanniter International
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Helios De Rosario, PhD
Organizational Affiliation
IBV-Gesmed, Spain
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mathew Summers, PhD
Organizational Affiliation
Sunshine Coast University, Australia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Aging Brain and Memory Clinic, Department of Neuroscience, University of Torino
City
Torino
ZIP/Postal Code
10126
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Innocenzo Rainero, MD, PhD
Phone
+39-011-633
Ext
4763
Email
innocenzo.rainero@unito.it
First Name & Middle Initial & Last Name & Degree
Elisa Rubino, MD, PhD
Phone
+39-011-633
Ext
4763
Email
elisa.rubino@unito.it

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
25783624
Citation
Choi J, Ahn A, Kim S, Won CW. Global Prevalence of Physical Frailty by Fried's Criteria in Community-Dwelling Elderly With National Population-Based Surveys. J Am Med Dir Assoc. 2015 Jul 1;16(7):548-50. doi: 10.1016/j.jamda.2015.02.004. Epub 2015 Mar 14.
Results Reference
background
PubMed Identifier
27324809
Citation
Kojima G, Taniguchi Y, Iliffe S, Walters K. Frailty as a Predictor of Alzheimer Disease, Vascular Dementia, and All Dementia Among Community-Dwelling Older People: A Systematic Review and Meta-Analysis. J Am Med Dir Assoc. 2016 Oct 1;17(10):881-8. doi: 10.1016/j.jamda.2016.05.013. Epub 2016 Jun 17.
Results Reference
background
PubMed Identifier
22426304
Citation
Shamliyan T, Talley KM, Ramakrishnan R, Kane RL. Association of frailty with survival: a systematic literature review. Ageing Res Rev. 2013 Mar;12(2):719-36. doi: 10.1016/j.arr.2012.03.001. Epub 2012 Mar 12.
Results Reference
background
PubMed Identifier
21968870
Citation
Panza F, Solfrizzi V, Frisardi V, Maggi S, Sancarlo D, Adante F, D'Onofrio G, Seripa D, Pilotto A. Different models of frailty in predementia and dementia syndromes. J Nutr Health Aging. 2011 Aug;15(8):711-9. doi: 10.1007/s12603-011-0126-1.
Results Reference
background
PubMed Identifier
11253156
Citation
Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56. doi: 10.1093/gerona/56.3.m146.
Results Reference
background

Learn more about this trial

Investigating My Active and Healthy Aging

We'll reach out to this number within 24 hrs